Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A):...
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective
About this item
Full title
Author / Creator
Kähler, Katharina C. , Gutzmer, Ralf , Angela, Yenny , Livingstone, Elisabeth , Lodde, Georg , Meiss, Frank , Rafei-Shamsabadi, David A. , Weyer-Fahlbusch, Sera S. , Nashan, Dorothée , Loquai, Carmen , Hassel, Jessica C. , Sachse, Michael M. M. , Maul, Lara V. , Heinzerling, Lucie , Heppt, Markus V. , Colapietro, Chiara , Rusch, Judith and Blome, Christine
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Introduction
Adjuvant treatment with immune checkpoint inhibitors, such as PD1-antibodies (ICI) ± CTLA4-antibodies (cICI) or targeted therapy with BRAF/MEK inhibitors (TT), has shown a significant improvement in disease-free survival (DFS) for high-risk melanoma patients. However, due to specific side effects, the choice of treatment is often in...
Alternative Titles
Full title
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective
Authors, Artists and Contributors
Author / Creator
Gutzmer, Ralf
Angela, Yenny
Livingstone, Elisabeth
Lodde, Georg
Meiss, Frank
Rafei-Shamsabadi, David A.
Weyer-Fahlbusch, Sera S.
Nashan, Dorothée
Loquai, Carmen
Hassel, Jessica C.
Sachse, Michael M. M.
Maul, Lara V.
Heinzerling, Lucie
Heppt, Markus V.
Colapietro, Chiara
Rusch, Judith
Blome, Christine
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11093864
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11093864
Other Identifiers
ISSN
1432-1335,0171-5216
E-ISSN
1432-1335
DOI
10.1007/s00432-024-05713-6
